 |
Corporate News
14-Dec-22
|
|
|
|
|
|
|
|
|
|
|
|
Biocon initiates clinical study of Itolizumab for Ulcerative Colitis in India
|
|
|
|
|
|
|
|
Biocon announced the initiation of the clinical study of Itolizumab in patients with Ulcerative Colitis (UC) in India, in collaboration with Equillium Inc. This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naïve patients with moderate to severely active UC.
Having obtained approval from the Drugs Controller General of India (DCGI), the study will cover several tertiary hospitals specialized in handling UC cases. The first patient who intended to participate in the study was screened on 01 December 2022.
|
|
|
|
Previous News |
Biocon gets USFDA nod for Liraglutide injection gVictoza
(
Hot Pursuit
-
13-Mar-26
09:24
)
|
|
|
Biocon Ltd soars 0.99%, gains for fifth straight session
(
Hot Pursuit
-
25-Feb-26
13:00
)
|
|
|
Biocon receives USFDA approval for Liraglutide
(
Corporate News
-
25-Feb-26
12:05
)
|
|
|
Biocon gets US FDA nod for chronic weight management drug Liraglutide
(
Hot Pursuit
-
25-Feb-26
09:42
)
|
|
|
Biocon consolidated net profit rises 472.91% in the December 2025 quarter
(
Results
-
Announcements
13-Feb-26
07:34
)
|
|
|
Biocon Ltd up for five straight sessions
(
Hot Pursuit
-
04-Feb-26
13:00
)
|
|
|
Biocon Ltd rises for third straight session
(
Hot Pursuit
-
16-Jan-26
13:05
)
|
|
|
Biocon concludes QIP issue of Rs 4,150 cr
(
Corporate News
-
15-Jan-26
12:10
)
|
|
|
Biocon to hold board meeting
(
Corporate News
-
14-Jan-26
10:04
)
|
|
|
Stock Alert: Biocon, Senco Gold, Jubilant Foodworks, Titan Company
(
Market Commentary
-
Stock Alert
07-Jan-26
07:58
)
|
|
|
Biocon Biologics to introduce three new biosimilar oncology assets
(
Corporate News
-
06-Jan-26
19:59
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|